Johnson & Johnson (NYSE:JNJ) Shares Sold by DDD Partners LLC

DDD Partners LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 23.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,500 shares of the company’s stock after selling 28,809 shares during the quarter. Johnson & Johnson makes up approximately 1.7% of DDD Partners LLC’s portfolio, making the stock its 26th biggest position. DDD Partners LLC’s holdings in Johnson & Johnson were worth $13,956,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC grew its position in shares of Johnson & Johnson by 20,130.0% during the third quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock worth $559,832,000 after buying an additional 3,437,397 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Johnson & Johnson by 228.1% during the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock worth $549,223,000 after buying an additional 2,356,359 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock worth $2,721,355,000 after buying an additional 1,729,281 shares in the last quarter. Holocene Advisors LP acquired a new position in shares of Johnson & Johnson during the third quarter worth about $225,040,000. Finally, FMR LLC grew its position in shares of Johnson & Johnson by 7.4% during the third quarter. FMR LLC now owns 18,316,920 shares of the company’s stock worth $2,968,440,000 after buying an additional 1,265,748 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $157.93 on Thursday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The business has a 50 day simple moving average of $148.34 and a 200-day simple moving average of $155.86. The stock has a market capitalization of $380.23 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 2.50 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the company posted $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.14%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on JNJ shares. Bank of America decreased their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Guggenheim boosted their target price on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Raymond James decreased their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, Barclays boosted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.